Who are TQB3616 capsules, Letrozole, Anastrozole, Tamoxifen's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Placebo capsules, Letrozole, Anastrozole, Tamoxifen, Placebo+endocrine therapy.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/tqb3616-capsules-letrozole-anastrozole-tamoxifen.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

TQB3616 capsules, Letrozole, Anastrozole, Tamoxifen — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

TQB3616 capsules, Letrozole, Anastrozole, Tamoxifen (TQB3616 capsules, Letrozole, Anastrozole, Tamoxifen) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Aromatase inhibitor, Selective estrogen receptor modulator. Area: Oncology.

phase 3 Aromatase inhibitor, Selective estrogen receptor modulator Aromatase, Estrogen receptor Oncology Small molecule Live · refreshed every 30 min

Target snapshot

TQB3616 capsules, Letrozole, Anastrozole, Tamoxifen (TQB3616 capsules, Letrozole, Anastrozole, Tamoxifen) — Chia Tai Tianqing Pharmaceutical Group Co., Ltd.. Letrozole and Anastrozole are non-steroidal, selective aromatase inhibitors, while Tamoxifen is a selective estrogen receptor modulator.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
TQB3616 capsules, Letrozole, Anastrozole, Tamoxifen TARGET	TQB3616 capsules, Letrozole, Anastrozole, Tamoxifen	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	phase 3	Aromatase inhibitor, Selective estrogen receptor modulator	Aromatase, Estrogen receptor
Placebo capsules, Letrozole, Anastrozole, Tamoxifen	Placebo capsules, Letrozole, Anastrozole, Tamoxifen	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	phase 3	Aromatase inhibitor, SERM	Aromatase, Estrogen receptor
Placebo+endocrine therapy	Placebo+endocrine therapy	Henan Cancer Hospital	phase 3	Endocrine therapy (aromatase inhibitor, selective estrogen receptor modulator, or androgen deprivation agent)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Aromatase inhibitor, Selective estrogen receptor modulator class)

Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). TQB3616 capsules, Letrozole, Anastrozole, Tamoxifen — Competitive Intelligence Brief. https://druglandscape.com/ci/tqb3616-capsules-letrozole-anastrozole-tamoxifen. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab